Sorafenib efficacy and side effects

Sorafenib (Sorafenib) has shown promising activity as a single agent in some cancers such as renal cell carcinoma (RCC), hepatocellular carcinoma and thyroid cancer. Clinical trials have demonstrated the efficacy and relative safety of sorafenib, and therefore, the drug is indicated for unresectable hepatocellular carcinoma. However, many patients exhibit resistance to hepatocytes and severe side effects. Many studies combine hepatocytes with other treatments to increase their effectiveness, reduce necessary doses or overcome drug resistance.

Sorafenib is a multi-kinase inhibitor that can extend the overall survival of patients with advanced hepatocellular carcinoma by nearly 3 months. Sorafenib simultaneously inhibits molecular components of the Raf–MEK–ERK signaling pathway, eliminating tumor growth and VEGFR-1, VEGFR-2, VEGFR-3, and PDGFR-β, thereby inhibiting neovascularization. By targeting two key pathways reported to play important roles in the pathogenesis of hepatocellular carcinoma, sorafenib may delay disease progression, and sorafenib is active in hepatocellular carcinoma, demonstrating the potential of molecularly targeted therapy in this tumor.

The overall incidence of serious adverse events from any cause was similar in both study groups, serious hepatobiliary adverse events (11%), serious bleeding events (9%), variceal bleeding ( Rates of renal failure (<1%), and cardiac ischemia or infarction (3%) were similar; the most common serious adverse events from any cause (other than death) were abnormal liver function (7%, respectively), diarrhea (5%), and ascites (5%).

The original drug of sorafenib has been launched in China and has entered the scope of medical insurance. Different regions have different reimbursement ratios, and the price after reimbursement may vary. SpecificationsThe price of 0.2g*60 tablets may be around 1,200 yuan. The original drug of sorafenib has also been launched overseas, and there are also generic drugs of sorafenib produced in other countries. The price of 0.2g*60 tablets produced by a Bangladesh pharmaceutical factory is around RMB 450 (the price may fluctuate due to the exchange rate). The ingredients of the original drug are basically the same as those of the generic drugs. For specific prices and drug details, please consult the medical consultant of Yaode.